Liraglutide Therapy: Complete Guide
Liraglutide is a once-daily GLP-1 receptor agonist and the first drug in its class approved for chronic weight management. It was approved as Victoza for type 2 diabetes in 2010 and as Saxenda for weight management in 2014, several years before semaglutide. Because it is dosed daily rather than weekly and produces less weight loss than the newer agents, it has largely been displaced by semaglutide and tirzepatide — but it remains FDA-approved, and generic versions began reaching the US market in 2024, which can make it substantially cheaper than the branded weekly drugs.
Fact-checking at PeptideProbe is editorial, not clinical. Our editors check claims, dosing figures, and trial results against primary sources; they are not licensed clinicians and do not provide medical review. Nothing here is medical advice — talk to a qualified healthcare provider before starting any therapy.
What is Liraglutide?
Liraglutide is a once-daily GLP-1 receptor agonist and the first drug in its class approved for chronic weight management. It was approved as Victoza for type 2 diabetes in 2010 and as Saxenda for weight management in 2014, several years before semaglutide. Because it is dosed daily rather than weekly and produces less weight loss than the newer agents, it has largely been displaced by semaglutide and tirzepatide — but it remains FDA-approved, and generic versions began reaching the US market in 2024, which can make it substantially cheaper than the branded weekly drugs.
How Liraglutide Works
Liraglutide works through specific biological pathways to produce its therapeutic effects. Consult with a qualified provider for detailed information about how this peptide therapy works for your specific condition.
Benefits & Uses
Established weight loss of roughly 8 percent of body weight at 56 weeks in the SCALE trial programme, improved glycaemic control, and a long real-world safety record, having been in clinical use since 2010. Generic availability can make it the least expensive FDA-approved GLP-1.
Clinical Evidence & Research
Clinical research on Liraglutide continues to evolve. Liraglutide has been evaluated in multiple clinical trials and has received FDA approval for specific indications.
Side Effects & Safety
Nausea, vomiting, diarrhoea and constipation, most pronounced during dose escalation. Injection site reactions. Serious but uncommon risks include pancreatitis and gallbladder disease. Carries a boxed warning for thyroid C-cell tumours based on rodent studies.
Dosing & Administration
Dosing protocols for Liraglutide should be determined by a qualified healthcare provider based on your individual health profile, treatment goals, and response to therapy. Self-dosing without medical supervision is not recommended.
Find Liraglutide Providers Near You
Search our directory for qualified providers offering Liraglutide therapy. Filter by location, telehealth, and more.
Browse ProvidersLiraglutide FAQ
Established weight loss of roughly 8 percent of body weight at 56 weeks in the SCALE trial programme, improved glycaemic control, and a long real-world safety record, having been in clinical use since 2010. Generic availability can make it the least expensive FDA-approved GLP-1.
Liraglutide therapy typically costs between $350 and $1350 per month, though prices vary by provider, location, and dosage.
Liraglutide has an FDA status of "FDA-approved". It has been approved by the FDA for specific indications. Your provider can explain the approved uses and any off-label applications.
Nausea, vomiting, diarrhoea and constipation, most pronounced during dose escalation. Injection site reactions. Serious but uncommon risks include pancreatitis and gallbladder disease. Carries a boxed warning for thyroid C-cell tumours based on rodent studies.
PeptideProbe lists 0 providers offering Liraglutide therapy. Use our directory to search by location, filter by telehealth availability, and compare providers.
Related Peptides
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.